✦ LIBER ✦

Reasons for Breakthrough CMV Disease in Patients Who Receive Preemptive Therapy

✍ Scribed by A. P. Limaye

Book ID: 117963599
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 411 KB
Volume: 12
Category: Article
ISSN: 1600-6135
DOI: 10.1111/j.1600-6143.2012.04229.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for treatment failures in p

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

✍ Einsele, H; Hebart, H; Kauffmann-Schneider, C; Sinzger, C; Jahn, G; Bader, P; Kl 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 74 KB

Preemptive and prophylactic ganciclovir

Preemptive and prophylactic ganciclovir therapy for CMV infection in heart transplant patients

✍ M.J Paniagua; M.G Crespo-Leiro; J.A Rodriguez; S Fojón; M.C Zúñiga; A Cañizares; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 51 KB

349: A CMV QPCR threshold of 1 × 104 cop

349: A CMV QPCR threshold of 1 × 104 copies/ml for preemptive therapy in CMV mismatched recipients does prevent CMV disease

✍ G. Parry; A. Krause; J. Forty; F.K. Gould 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Role of CMV antigenemia directed preempt

Role of CMV antigenemia directed preemptive therapy with ganciclovir for the prevention of cmv disease at 6 months in lung transplant recipients

✍ S Husain; K.R McCurry; J.H Dauber; R Zomak; P Williams; S Kusne 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Prophylaxis of cytomegalovirus disease w

Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy

✍ E Morales; A Andrés; E González; J.C Herrero; M.A Muñoz; M Ortiz; B Espejo; C Lu 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Quantitation of cytomegalovirus (CMV) DN

Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy

✍ Karine Gourlain; Dominique Salmon; Elyanne Gault; Catherine Leport; Christine Ka 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract In HIV‐infected patients treated with highly active antiretroviral therapy (HAART) included in the Predivir cohort, we have evaluated the usefulness of CMV DNA quantitation by a TaqMan^®^ PCR assay from peripheral blood leukocytes (PBLs) to predict CMV disease occurrence. In parallel wi